Reneo Pharmaceuticals Inc expected to post a loss of 44 cents a share - Earnings Preview

Onkure Therapeutics

07/05/2024 14:03

* Reneo Pharmaceuticals Inc  RPHM.OQ   RPHM.O  is expected
to show
no change in quarterly revenue when it reports  results on May 7
for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Reneo Pharmaceuticals
Inc is
for a loss of 44 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 4
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 6.5%
in the last three months. ​
    * Wall Street's median 12-month price target for Reneo
Pharmaceuticals Inc is $1.35​, below​ its last closing price
of $1.73. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.56       -0.58      -0.71     Missed  -22.9
 Sep. 30 2023  -0.57       -0.57      -0.57     Met     0.3
 Jun. 30 2023  -0.50       -0.52      -0.65     Missed  -25.8​
 Jan. 1 0001   -0.59       -0.60      -0.60     Met     0.7
 ​​Dec.                    -0.60      -0.56     Beat    6.8
 31 2022                                                
 Sep. 30 2022  -0.57       -0.57      -0.53     Beat    7.3​
 Jan. 1 0001   -0.58       -0.58      -0.50     Beat    14.1
 Mar. 31 2022  -0.52       -0.54      -0.53     Beat    2.5
 This summary was machine generated May 7 at 13:03 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)